Insilico Doses First Patient in AI-Driven Phase 3 IPF Trial
New York, New York, September 10, 2026 Insilico Medicine has announced that the first patient has been dosed in...
Dabogratinib
Advertisement
IDEAYA and Servier Launch Phase 3 Uveal Melanoma Trial
South San Francisco, California and Paris, France, September 9, 2026 IDEAYA Biosciences and Servier have announced that the first...
Tyra Reports Phase 2 Dabogratinib Results in Bladder Cancer
San Diego, California, September 10, 2026 Tyra Biosciences, Inc. has reported initial results from the Phase 2 SURF302 clinical...
Tyra to Present Dabogratinib Phase 2 Bladder Cancer Data
Carlsbad, California, USA, September 4, 2026 Tyra Biosciences, Inc. has announced that it will host a conference call and...
Advertisement
